Designing suitable PULL incentives for the European AMR market
On April 2024, the European Parliament (EP) adopted its position at first reading on the revision of the General Pharmaceutical Legislation (GPL). As the Council of the European Union (EU) is now actively preparing its General Approach, notably on the incentives for the development of ‘priority antimicrobials’, the BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on three pillars:
1) Sufficient size: Any PULL incentive solution should reach the EU “fair share” (€1 to 1.5 billion per drug).
2) Predictability: The PULL incentive solution should aim to fairly share the burden of uncertainties between payers and developers.
3) Combination of mechanisms: To meet everyone’s expectations, the PULL incentive solution should combine mechanisms that reward innovation (e.g. exclusivity voucher)
and some ensuring access (e.g. a subscription-type model).
We call on EU policymakers to urgently take action and set up the long-awaited PULL mechanism.
Click here to find out more.